JMP Securities Reiterates Market Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)

JMP Securities analyst Jonathan Wolleben reiterated a Market Outperform rating and $19.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).

The analyst commented, “We like that the data continue to support the safety of an oral on-demand therapy in even severe laryngeal attacks. KALV will also have two posters during Friday’s “Quality Improvement, Outcomes, and Costs” session discussing barriers to timely on-demand treatment and the injection burden in adolescent patients with HAE — these could be particularly interesting as they highlight the unmet need sebetralstat will address.”

For an analyst ratings summary and ratings history on Kalvista Pharmaceuticals Inc click here. For more ratings news on Kalvista Pharmaceuticals Inc click here.

Shares of Kalvista Pharmaceuticals Inc closed at $9.76 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy